United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company focused on developing and commercializing unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company is known for its innovative therapies, including Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. These products have significantly contributed to the company's financial success.
On July 31, 2025, Andrew Fein from H.C. Wainwright set a price target of $400 for UTHR. At that time, the stock was priced at $281.95, suggesting a potential increase of approximately 41.87%. This optimistic outlook aligns with the company's recent financial performance, as highlighted in their Q2 2025 earnings call.
During the Q2 2025 earnings call, United Therapeutics reported record financial results. The company's total revenues increased by 12% year-over-year, reaching $798.6 million, up from $714.9 million in the same period last year. This growth was driven by strong sales of key products, showcasing the company's robust market presence.
Despite the positive financial results, UTHR's stock price experienced a decrease of 5.24%, or $15.61, bringing it to $281.95. The stock fluctuated between $280.35 and $300.47 on the day of the earnings call. Over the past year, UTHR has seen a high of $417.82 and a low of $266.98, indicating significant volatility.
United Therapeutics' market capitalization is approximately $12.72 billion, with a trading volume of 872,530 shares on the NASDAQ. The company's strong financial performance and strategic initiatives, as discussed in the earnings call, support the optimistic price target set by Andrew Fein, suggesting potential growth for investors.
